Logo

UroGen Pharma Ltd.

URGN

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102, which is in Phase III… read more

Healthcare

Biotechnology

6 years

USD

Exclusive to Premium users

Price

per share adjusted in USD

$18.88

Price

+0.43%

$0.08

Market Cap

$873.466m

Small

Price/Earnings

-

Premium

3y Avg

Premium

5y Avg

Financials Overview

Key metrics over the past few years

-

EBITDA Margin

-

Net Profit Margin

-

Free Cash Flow Margin
Revenue

$91.871m

-

1y CAGR

-

3y CAGR

-

5y CAGR
Earnings

-$138.431m

-

1y CAGR

-

3y CAGR

-

5y CAGR
EPS

-$3.25

-

1y CAGR

-

3y CAGR

-

5y CAGR
Book Value

-$46.458m

$247.618m

Assets

$294.076m

Liabilities

$124.949m

Debt
Debt to Assets

50.5%

-1.2x

Debt to EBITDA
Free Cash Flow

-$107.394m

-

1y CAGR

-

3y CAGR

-

5y CAGR

Financial Reports

Earnings and other important metrics. Amounts in USD.
No items found.
Press Releases
Statements and updates from the company
↑ TopSummaryPriceFinancialsPress Releases